Anthony W. Tolcher

Also affiliated with Nektar Therapeutics (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma”.

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0974

N/A

1.3DataRank · unranked

44 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3313

N/A

0.659DataRank · unranked

80 citations

Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen +12 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v1

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

Data from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

(2023)10.1158/1078-0432.c.6727617.v2

N/A

0DataRank · unranked

0 citations

Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani +14 more

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2409

N/A

0DataRank · unranked

45 citations

Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, Marta Enderlin, Christine Hicking +6 more

A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1552

N/A

0DataRank · unranked

12 citations

Shane A. Olwill, Erika Hamilton, Anthony W. Tolcher, Paula R. Pohlmann, Stephen V. Liu +16 more